Faculty profile

Jean-Pierre Julien

ResearcherPsychiatrieUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Jean-Pierre Julien

Researcher

Psychiatrie

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
15 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2016.
Supervisor on 1 trainee award (1 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Amyotrophic Lateral Sclerosis Neuroinflammation Transgenic Mice Crc Alzheimer'S Disease Fontotemporal Dementia Neurodegeneration Superoxide Dismutase

Latest papers

Engineered autophagy receptors administered with extracellular vesicles eliminate pathological Tau and TDP-43.
Nature biomedical engineering · 2026
Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025 · senior author
Virus-mediated delivery of single-chain antibody targeting TDP-43 protects against neuropathology, cognitive impairment and motor deficit caused by chronic cerebral hypoperfusion.
Experimental neurology · 2025 · senior author

All 78 publications

Latest funding

Canada Research Chair - Tier 1
CIHR · 2016 · Nominated PI
$1,400,000
La génération d'un modèle murin double transgénique Ubiquiline-2(P497H)/TDP-43(A315T) comme modèle animal de sclérose latérale amyotrophique.
CIHR · 2015 · Supervisor
$105,000
From pathogenic pathways to novel therapeutic strategies in amyotrophic lateral sclerosis
CIHR · 2014 · Nominated PI
$2,821,594

All 9 grants and awards

78 publications.

Engineered autophagy receptors administered with extracellular vesicles eliminate pathological Tau and TDP-43.

Guo H, Savard A, Manser C, Dutta K, Taylor JA, Rousseaux MWC, Pozzi S, Julien JP, Baird S, Gibbings D

Nature biomedical engineering2026

DOI: 10.1038/s41551-026-01774-9 PMID: 42649384

Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS.

Poulin-Brière A, Pozzi S, Julien JP

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025Senior author

DOI: 10.1016/j.neurot.2025.e00737 PMID: 40940222

Virus-mediated delivery of single-chain antibody targeting TDP-43 protects against neuropathology, cognitive impairment and motor deficit caused by chronic cerebral hypoperfusion.

Chami AA, Gravel C, Weng YC, Kriz J, Julien JP

Experimental neurology2025Senior author

DOI: 10.1016/j.expneurol.2025.115138 PMID: 39778789

Inhibition of NF-κB with an Analog of Withaferin-A Restores TDP-43 Homeostasis and Proteome Profiles in a Model of Sporadic ALS.

Mishra PS, Phaneuf D, Boutej H, Picher-Martel V, Dupre N, Kriz J, Julien JP

Biomedicines2024Senior author

DOI: 10.3390/biomedicines12051017 PMID: 38790979

Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.

Pokrishevsky E, DuVal MG, McAlary L, Louadi S, Pozzi S, Roman A, Plotkin SS, Dijkstra A, Julien JP, Allison WT, Cashman NR

The Journal of biological chemistry2024

DOI: 10.1016/j.jbc.2024.107207 PMID: 38522514

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.

Pelaez MC, Desmeules A, Gelon PA, Glasson B, Marcadet L, Rodgers A, Phaneuf D, Pozzi S, Dutchak PA, Julien JP, Sephton CF

Acta neuropathologica communications2023

DOI: 10.1186/s40478-023-01671-1 PMID: 37974279

Transactive response DNA-binding protein 43 is enriched at the centrosome in human cells.

Bodin A, Greibill L, Gouju J, Letournel F, Pozzi S, Julien JP, Renaud L, Bohl D, Millecamps S, Verny C, Cassereau J, Lenaers G, Chevrollier A, Tassin AM, Codron P

Brain : a journal of neurology2023

DOI: 10.1093/brain/awad228 PMID: 37410912

Ultrasensitive digital immunoassays for SOD1 conformation in amyotrophic lateral sclerosis.

Morichon L, Hirtz C, Tiers L, Mezghrani A, Raoul C, Esselin F, La Cruz E, Julien JP, Camu W, Lehmann S

Bioanalysis2023

DOI: 10.4155/bio-2023-0103 PMID: 37650499

Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A.

Nath B, Phaneuf D, Julien JP

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023Senior author

DOI: 10.1007/s13311-023-01393-1 PMID: 37268847

Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.

De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami AA, Mele A, Vidatic L, Kriz J, Julien JP, Apic G, Russell RB, Rogelj B, Cannon JR, Baralle M, Agosta F, Hecimovic S, Mazzini L, Buratti E, Munitic I

Biomedicines2023

DOI: 10.3390/biomedicines11061599 PMID: 37371694

Canada Research Chair - Tier 1

Nominated PICIHR2016Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Julien, Jean-Pierre

Keywords: Crc

$1,400,000

La génération d'un modèle murin double transgénique Ubiquiline-2(P497H)/TDP-43(A315T) comme modèle animal de sclérose latérale amyotrophique.

SupervisorCIHR2015Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Picher-Martel, Vincent

Keywords: Modèle Animal; Nf-Kb; Sla; Souris; Tdp-43; Ubqln2

$105,000

From pathogenic pathways to novel therapeutic strategies in amyotrophic lateral sclerosis

Nominated PICIHR2014Foundation Grant

Principal investigators: Julien, Jean-Pierre

Keywords: Alzheimer'S Disease; Amyotrophic Lateral Sclerosis; Fontotemporal Dementia; Neuroinflammation; Transgenic Mice

$2,821,594

Therapeutic nanobodies for amyotrophic lateral sclerosis

Nominated PICIHR2013Operating Grant - Priority Announcement: ALS Canada Research Fund

Principal investigators: Julien, Jean-Pierre

Keywords: Amyotrophic Lateral Sclerosis; Neurodegeneration; Neuroinflammation; Superoxide Dismutase; Tdp-43; Transgenic Mice

TDP-43-mediated pathogenic pathways in ALS and new experimental therapeutics

Nominated PICIHR2011Operating Grant

Principal investigators: Julien, Jean-Pierre

Keywords: Amyotrophic Lateral Sclerosis; Neurodegeneration; Neuroinflammation; Superoxide Dismutase; Transgenic Mice

$751,740

Pathogenic mechanisms associated with neurofilament disorganization

Nominated PICIHR2010Operating Grant - Priority Announcement: Neuromuscular Research

Principal investigators: Julien, Jean-Pierre

Keywords: Amyotrophic Lateral Sclerosis; Axonal Transport; Cytoskeleton; Microtubules; Neurofilaments; Neuropathies; Transgenic Mice

$429,658

CANADA RESEARCH CHAIRHOLDER / TITULAIRE DE CHAIRE DE RECHERCHE DU CANADA

Nominated PICIHR2009Canada Research Chairs - CIHR Funded - Tier 1

Principal investigators: Julien, Jean-Pierre

Keywords: Crc

$1,400,000

Induced pluripotent stem cells for ALS research and drug discovery

Nominated PICIHR2009Emerging Team Grant: Regenerative Medicine and Nanomedicine - LOI

Principal investigators: Julien, Jean-Pierre; Berthod, François; Dupre, Nicolas; Kriz, Jasna; Rafuse, Victor F; Rouleau, Guy A; Strong, Michael J; Vande Velde, Christine Diane C

Keywords: Als; Induced Pluripotent Stem Cells; Motor Neuron

Superoxide dismutase-1 abnormalities associated with sporadic ALS

Nominated PICIHR2008Operating Grant

Principal investigators: Julien, Jean-Pierre

Keywords: Amyotrophic Lateral Sclerosis; Protein Aggregation; Protein Misfolding; Superoxide Dismutase

$397,008

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Jean-Pierre Julien

Research

Latest papers

Latest funding

Engineered autophagy receptors administered with extracellular vesicles eliminate pathological Tau and TDP-43.

Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS.

Virus-mediated delivery of single-chain antibody targeting TDP-43 protects against neuropathology, cognitive impairment and motor deficit caused by chronic cerebral hypoperfusion.

Inhibition of NF-&#x3ba;B with an Analog of Withaferin-A Restores TDP-43 Homeostasis and Proteome Profiles in a Model of Sporadic ALS.

Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-&#x3ba;B inhibition.

Transactive response DNA-binding protein 43 is enriched at the centrosome in human cells.

Ultrasensitive digital immunoassays for SOD1 conformation in amyotrophic lateral sclerosis.

Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A.

Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.

Frequent collaborators

Jasna Kriz

Silvia Pozzi

Richard Robitaille

Richard Robitaille

Francois Gros-Louis

Martin Parent

Ekaterina Rogaeva

Xiao-Yan Wen

Angela Genge

Lawrence Korngut

Victor Rafuse

Janice Robertson

Denis Soulet

Pierre Drapeau

Serge Rivest

Derrick Gibbings

Steve Lacroix

Inhibition of NF-κB with an Analog of Withaferin-A Restores TDP-43 Homeostasis and Proteome Profiles in a Model of Sporadic ALS.

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.